Pfizer Global Regulatory Affairs
Pfizer Inc.
400 Arcola Road Collegeville, PA 19426

Global Product Development

21 August 2021

Marion Gruber, Ph.D.
Director
Office of Vaccines Research and Review
Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Avenue
WO71, G112
Silver Spring, MD 20993-0002

Re: BLA 125742

COVID-19 mRNA Vaccine (BNT162/PF-07302048)

Response to FDA 21 August 2021 Information Request

Dear Dr. Gruber,

Reference is made to the Biologics License Application (BLA) submitted 18 May 2021 for the COVID-19 mRNA Vaccine (BNT162/PF-07302048) developed by BioNTech and Pfizer under BB-IND 19736 for the prevention of COVID-19 caused by SARS-CoV-2 in individuals ≥16 years of age.

The purpose of this submission is to respond to CBER's 21 August 2021 Information Request, received via email from Captain Michael Smith, PhD (CBER). Pfizer/BioNTech is requested to review and re-submit the list of Postmarketing Requirement and Postmarketing Commitment studies and dates with a commitment to conduct all of these studies in the timeframes noted. The Response to FDA 21 August 2021 Information Request is provided in Module 1.11.3.

Should you have any questions regarding this submission, or require additional information, please contact me via phone at 215-280-5503; via facsimile at 845-474-3500; or via e-mail at elisa.harkinstull@pfizer.com.

Sincerely,

Elisa Harkins
Global Regulatory Lead
Global Regulatory Affairs – Vaccines

CC: Ramachandra S. Naik, Ph.D.
Captain Michael Smith, Ph.D.
Laura Gottshalk, Ph.D.